BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results